It is expected that a price bounce should occur soon.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 8 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
The Moving Average Convergence Divergence (MACD) for ASMB just turned positive on October 20, 2026. Looking at past instances where ASMB's MACD turned positive, the stock continued to rise in 31 of 42 cases over the following month. The odds of a continued upward trend are 74%.
Following a +5.47% 3-day Advance, the price is estimated to grow further. Considering data from situations where ASMB advanced for three days, in 215 of 269 cases, the price rose further within the following month. The odds of a continued upward trend are 80%.
ASMB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The 10-day moving average for ASMB crossed bearishly below the 50-day moving average on September 21, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 16 of 16 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.
The 50-day moving average for ASMB moved below the 200-day moving average on October 23, 2026. This could be a long-term bearish signal for the stock as the stock shifts to an downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ASMB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 86%.
The Aroon Indicator for ASMB entered a downward trend on October 26, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. ASMB’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.310) is normal, around the industry mean (3.037). P/E Ratio (15.863) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (5.568) is also within normal values, averaging (439.237).
The Tickeron SMR rating for this company is 89 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ASMB’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where ENTA advanced for three days, in 209 of 270 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 41 of 60 cases where ENTA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 68%.
The Moving Average Convergence Divergence (MACD) for ENTA just turned positive on October 26, 2026. Looking at past instances where ENTA's MACD turned positive, the stock continued to rise in 35 of 54 cases over the following month. The odds of a continued upward trend are 65%.
ENTA may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Momentum Indicator moved below the 0 level on October 12, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ENTA as a result. In 67 of 79 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 85%.
ENTA moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ENTA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 84%.
The Aroon Indicator for ENTA entered a downward trend on October 06, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron PE Growth Rating for this company is 29 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Valuation Rating of 55 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.458) is normal, around the industry mean (3.037). P/E Ratio (-4.959) is within average values for comparable stocks, (-1.223). Projected Growth (PEG Ratio) (0.550) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (135.883) among similar stocks. P/S Ratio (5.285) is also within normal values, averaging (439.237).
The Tickeron Price Growth Rating for this company is 58 (best 1 - 100 worst), indicating steady price growth. ENTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ENTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
ASMB | ENTA | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 7 | 40 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 85 Overvalued | 55 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | |
SMR RATING 1..100 | 89 | 98 | |
PRICE GROWTH RATING 1..100 | 79 | 58 | |
P/E GROWTH RATING 1..100 | 97 | 29 | |
SEASONALITY SCORE 1..100 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
ENTA's Valuation (55) in the Biotechnology industry is in the same range as ASMB (85) in the Pharmaceuticals Other industry. This means that ENTA’s stock grew similarly to ASMB’s over the last 12 months.
ENTA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as ASMB (100) in the Pharmaceuticals Other industry. This means that ENTA’s stock grew similarly to ASMB’s over the last 12 months.
ASMB's SMR Rating (89) in the Pharmaceuticals Other industry is in the same range as ENTA (98) in the Biotechnology industry. This means that ASMB’s stock grew similarly to ENTA’s over the last 12 months.
ENTA's Price Growth Rating (58) in the Biotechnology industry is in the same range as ASMB (79) in the Pharmaceuticals Other industry. This means that ENTA’s stock grew similarly to ASMB’s over the last 12 months.
ENTA's P/E Growth Rating (29) in the Biotechnology industry is significantly better than the same rating for ASMB (97) in the Pharmaceuticals Other industry. This means that ENTA’s stock grew significantly faster than ASMB’s over the last 12 months.
| ASMB | ENTA | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 90% | N/A |
| Stochastic ODDS (%) | 2 days ago 90% | 2 days ago 68% |
| Momentum ODDS (%) | N/A | 2 days ago 85% |
| MACD ODDS (%) | 2 days ago 74% | 2 days ago 65% |
| TrendWeek ODDS (%) | 2 days ago 86% | 2 days ago 79% |
| TrendMonth ODDS (%) | 2 days ago 83% | 2 days ago 79% |
| Advances ODDS (%) | 8 days ago 80% | 2 days ago 77% |
| Declines ODDS (%) | 2 days ago 86% | 14 days ago 84% |
| BollingerBands ODDS (%) | 2 days ago 84% | 2 days ago 69% |
| Aroon ODDS (%) | 2 days ago 87% | 2 days ago 88% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ASMB’s FA Score shows that 0 FA rating(s) are green while ENTA’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ASMB’s TA Score shows that 5 TA indicator(s) are bullish while ENTA’s TA Score has 4 bullish TA indicator(s).
ASMB (@Biotechnology) experienced а -2.43% price change this week, while ENTA (@Biotechnology) price change was +5.17% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was +4.32%. For the same industry, the average monthly price growth was -10.69%, and the average quarterly price growth was -13.52%.
ASMB is expected to report earnings on Nov 09, 2026.
ENTA is expected to report earnings on Nov 16, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.
A.I.dvisor indicates that over the last year, ASMB has been loosely correlated with ENTA. These tickers have moved in lockstep 43% of the time. This A.I.-generated data suggests there is some statistical probability that if ASMB jumps, then ENTA could also see price increases.
| Ticker / NAME | Correlation To ASMB | 1D Price Change % | ||
|---|---|---|---|---|
| ASMB | 100% | -0.86% | ||
| ENTA - ASMB | 43% Loosely correlated | +3.09% | ||
| FDMT - ASMB | 42% Loosely correlated | +2.13% | ||
| VYGR - ASMB | 42% Loosely correlated | +0.57% | ||
| EDIT - ASMB | 41% Loosely correlated | N/A | ||
| IMMX - ASMB | 41% Loosely correlated | -1.10% | ||
More | ||||
| 1 Day | |||
|---|---|---|---|
| CRYPTO / NAME | Price $ | Chg $ | Chg % |
| FIO.X | 0.000378 | 0.000005 | +1.22% |
| FIO Protocol cryptocurrency | |||
| BNT.X | 0.297130 | 0.000824 | +0.28% |
| Bancor cryptocurrency | |||
| LINK.X | 11.378974 | -0.055415 | -0.48% |
| Chainlink cryptocurrency | |||
| GNS.X | 0.388879 | -0.006616 | -1.67% |
| Gains Network cryptocurrency | |||
| APE.X | 0.122149 | -0.003537 | -2.81% |
| ApeCoin cryptocurrency | |||